GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR
Clinical trials for GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR explained in plain language.
Never miss a new study
Get alerted when new GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR trials appear
Sign up with your email to follow new studies for GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Radioactive therapy plus surgery: a new one-two punch for hard-to-treat tumors?
Disease control Recruiting nowThis early-phase study tests whether giving a radioactive drug (PRRT) both before and after surgery is safe and doable for people with advanced gastroenteropancreatic neuroendocrine tumors (NETs). About 10 adults whose tumors have spread to lymph nodes or liver and who are eligib…
Matched conditions: GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR
Phase: PHASE1 • Sponsor: Stanford University • Aim: Disease control
Last updated May 26, 2026 03:34 UTC
-
New Alpha-Particle therapy shows promise for Hard-to-Treat tumors
Disease control Recruiting nowThis study tests a new treatment called [212Pb]VMT-α-NET for people with advanced tumors that have a specific marker (SSTR2). The treatment delivers targeted radiation to kill cancer cells while sparing healthy tissue. About 300 adults with neuroendocrine tumors or meningioma tha…
Matched conditions: GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR
Phase: PHASE1, PHASE2 • Sponsor: Perspective Therapeutics • Aim: Disease control
Last updated May 22, 2026 14:04 UTC
-
New hope for tough gut tumors: RYZ101 trial targets patients who failed standard therapy
Disease control Recruiting nowThis study tests a new drug called RYZ101 in people with advanced neuroendocrine tumors of the gut or pancreas that cannot be removed by surgery and have grown after prior treatment with a type of radiation therapy (177Lu). The trial has two parts: first, finding the best dose, t…
Matched conditions: GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR
Phase: PHASE3 • Sponsor: RayzeBio, Inc. • Aim: Disease control
Last updated May 22, 2026 13:52 UTC
-
New hope for rare cancers: immunotherapy combo tested in national trial
Disease control Recruiting nowThis study tests a combination of two immunotherapy drugs (domvanalimab and zimberelimab) in people with five types of rare advanced cancers that have stopped responding to standard treatment. The goal is to see if this treatment can control the cancer better than older therapies…
Matched conditions: GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR
Phase: PHASE2 • Sponsor: Hospices Civils de Lyon • Aim: Disease control
Last updated May 22, 2026 13:51 UTC
-
New hope for rare gut tumors: PRRT under the microscope
Disease control Recruiting nowThis study is tracking 50 adults with neuroendocrine tumors (a rare type of cancer) to see how well a treatment called PRRT works. PRRT uses a radioactive drug to target and kill cancer cells. Researchers will monitor tumor shrinkage, survival time, and side effects to better und…
Matched conditions: GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR
Sponsor: Methodist Health System • Aim: Disease control
Last updated May 20, 2026 11:54 UTC
-
Radioactive drug RYZ401 targets Hard-to-Treat tumors in first human trial
Disease control Recruiting nowThis early-stage study tests a new radioactive drug called RYZ401 in people with neuroendocrine tumors and other solid tumors that have a specific protein on their surface. The main goals are to find the safest dose and schedule, and to see if the drug can shrink tumors. About 10…
Matched conditions: GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR
Phase: PHASE1 • Sponsor: RayzeBio, Inc. • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
New study aims to predict which patients benefit from targeted radiation for rare gut tumors
Knowledge-focused Recruiting nowThis study enrolls 80 people with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs) who are scheduled for peptide receptor radionuclide therapy (PRRT). Researchers will use advanced PET-MRI scans and genetic profiling before, during, and after treatment to identify…
Matched conditions: GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR
Phase: NA • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated May 26, 2026 03:43 UTC
-
Could diet change the course of slow-growing gut tumors?
Knowledge-focused Recruiting nowThis study looks at whether nutrition is linked to better outcomes in adults with gastroenteropancreatic neuroendocrine tumors (NETs), a slow-growing cancer of the digestive system. Researchers will check 100 patients for signs of malnutrition and track their health over time. Th…
Matched conditions: GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR
Sponsor: University Hospital, Strasbourg, France • Aim: Knowledge-focused
Last updated May 15, 2026 11:56 UTC